surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 In the SURMOUNT-1 trial (published

Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)

A sea of biosynthesis: marine and natural products meet the molecular age

Food-chain selenium and human health: emphasis on intake

Photo by Innerbody Research Weight loss is a struggle for most people

Funding This research was supported by the Arkansas Biosciences Institute (Little Rock, AR, USA), The Jonty Foundation (St Paul, MN), The Autism Research Institute (San Diego, CA), the Gupta Family Foundation (Atherton, CA), The Jane Bostford Johnson Foundation (New York, NY) and the Jager Family Foundation (Chicago, IL)